ONTY Oncothyreon Inc . featured news, full reports, and detailed charts
Oncothyreon Inc . (ONTY) Wrap Up:
This annual report on Form 10-K, including the “Management’s Discussion and Analysis of Financial Condition and Results of Operation” section in Item 7 of this report, and other materials accompanying this annual report on Form 10-K contain forward-looking statements or incorporate by reference forward-looking statements. You should read these statements carefully because they discuss future expectations, contain projections of future results of operations or financial condition, or state other “forward-looking” information. These statements relate to our, or in some cases our partners’ future plans, objectives, expectations, intentions and financial performance and the assumptions that underlie these statements. ... More..."http://secfilings.nasdaq.com/edgar_conv_html%2f2008%2f03%2f17%2f0000950134-08-004849.html#FIS_BUSINESS"www.oncothyreon.com
18 Employees
Founded in 1985
Oncothyreon Inc (ONTY:NASDAQ)
LAST $4.60 USD
CHANGE TODAY -0.06 -1.29%
VOLUME 29.6K
As of 10:30 AM 11/20/09 All times are local (Market data by Reuters is delayed by at least 15 minutes).
Snapshot of Oncothyreon Inc (ONTY)
|
OPEN
$4.66
|
PREVIOUS CLOSE
$4.66
|
|
|
DAY HIGH
$4.70
|
DAY LOW
$4.56
|
|
|
52 WEEK HIGH
08/4/09 - $7.77
|
52 WEEK LOW
12/29/08 - $0.65
|
|
|
MARKET CAP
118.0M
|
AVERAGE VOLUME 3 mo
549.0K
|
|
|
DILUTED EPS TTM
$-0.19
|
SHARES OUTSTANDING
25.7M
|
|
|
ONTY Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
ONTY Top Compensated Officers
Dr. Robert Kirkman M.D.
Chief Executive Officer, President and Direct...
Age: 59
Total Annual Compensation: $375.0K
Mr. Gary Christianson
Chief Operating Officer
Age: 53
Total Annual Compensation: $247.2K
Executives, Board Directors
Compensation as of Fiscal Year 2008.
Key developments for Oncothyreon Inc (ONTY)
Oncothyreon Inc. Reports Unaudited Consolidated Cash Flow Results for the Nine Months Ended September 30, 2009
11/13/2009
Oncothyreon Inc. reported unaudited consolidated cash flow results for the nine months ended September 30, 2009. For the nine months, the company's net cash used in operating activities was $7,928,000 compared to $12,196,000 a year ago. Purchase of plant and equipment was $462,000.
Oncothyreon Inc, Q3 2009 Earnings Call, Nov-11-2009
11/2/2009
Oncothyreon Inc, Q3 2009 Earnings Call, Nov-11-2009
Oncothyreon Inc. to Report Q3, 2009 Results on November 11, 2009
11/2/2009
Oncothyreon Inc. announced that they will report Q3, 2009 results after the market closes on November 11, 2009.
ONTY Competitors
| Company | Last | Change |
| Antigenics Inc | $0.92 USD | -0.0399 |
| AVI BioPharma Inc | $1.49 USD | -0.06 |
| Cerus Corporation | $1.98 USD | -0.05 |
| Progenics Pharmaceuticals Inc | $3.97 USD | -0.0199 |
| Vical Inc | $3.13 USD | -0.05 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | ONTY | Industry Range |
| Price/Earnings | 16.6x |
|
| Price/Sales | 3.2x |
|
| Price/Book | 5.9x |
|
| Price/Cash Flow | 19.0x |
|
| TEV/Sales | 2.7x |
|
|
ONTY |
||
|
ONTY transactions
| Type Date |
Target |
|
Private Placement
August 4, 2009 |
-- |
More Recent News About Oncothyreon Inc .
More news for ONTY
Oncothyreon announces webcast of third quarter 2009 financial results conference call
Copyright © 2009 Yahoo! All rights reserved. Privacy Policy - Terms of Service - Copyright Policy - Report Problems Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quote data delayed 15 minutes for Nasdaq, NYSE and Amex. Real-Time continuous streaming quotes are available through our premium service. You may turn streaming quotes on or off. All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Yahoo! is not an investment adviser and does not provide, endorse or review any information or data contained herein....Click here to read the whole Article (external link)
Biotech Mailbag: The Reason(s) for This Selloff
Stock quotes in this article: GILD , ONTY , IMGN , ...Click here to read the whole Article (external link)
Q3 2009 Oncothyreon Inc. Earnings Release - After Market Close
Earnings Announcements for Wednesday, November 11CompanySymbolTimeConferenceCallACEGAS SPAAEG.MITime Not SuppliedADLINK INTERNET AGLKI.FTime Not SuppliedAdvance Auto PartsAAPAfter Market CloseListenAEGEAN MARINE PETROLEUM NETWORK INCANWAfter Market CloseListenAeterna Zentaris Inc.AEZSBefore Market OpenAlliant Techsystems Inc.ATKAfter Market CloseListenALLOT COMMUNICATIONS LTDALLTTime Not SuppliedListenAmerican BiltriteABLAfter Market CloseAmerican DG Energy Inc.ADGEBefore Market OpenAmeriGas PartnersAPUBefore Market OpenListenANATOLIA MINERALS DEV LTDALIAF.PKTime Not SuppliedApplied MaterialsAMATAfter Market CloseListenARACRUZ CELULOSE S AARABefore Market OpenARCADIS NVARCVF.PKBefore Market OpenArden GroupARDNATime Not SuppliedArotech CorporationARTXAfter Mar...Click here to read the whole Article (external link)
Oncothyreon reports third quarter 2009 financial results & provides product pipeline update
SEATTLE, Nov. 11 /PRNewswire-FirstCall/ - Oncothyreon Inc. (NASDAQ: ONTY - News) today reported financial results for the three and nine months ended September 30, 2009 and provided a product pipeline update. Management will hold a conference call today at 4:30 p.m. ET, 1:30 p.m. PT (see below for details). Oncothyreon reported a loss from operations of $2.8 million for the three months ended September 30, 2009, compared with a loss from operations of $3.6 million for the comparable period in 2008. Oncothyreon also reported a loss from operations of $9.0 million for the nine months ended September 30, 2009, compared with a loss from operations of $13.7 million for the comparable period in 2008. For both the three-month and nine-month periods, the decrease in loss from operations was primarily the result of decreased research and development, manufacturing and general and administrative expenses, offset by a decrease in revenue.Operating expenses for the three and nine months ended September 30, 2009 were $2.8 million and $9.1 million respectively, compared with $4.4 million and $17.7 million for the comparable periods in 2008. Combined research and development and manufacturing expenses decreased to $1.3 million for the three months ended September 30, 2009 from $2.1 million for the three months ended September 30, 2008, and to $4.0 million from $9.5 million for the nine month periods, primarily as a result of the cessation of manufacturing activities for Stimuvax and the transfer of our Edmonton, Alberta facility to Merck KG...Click here to read the whole Article (external link)
Oncothyreon Q3 loss grows to $5.9M
ONLINE: home | business news | small business | sales & marketing | real estate | events | community | careers | city guide | advertise | about us | rss PRINT: subscribe | renew | advertise | book of lists | business intelligence | classifieds | view digital edition | ...Click here to read the whole Article (external link)
ONCOTHYREON INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
Show all filings for ONCOTHYREON INC. | Request a Trial to NEW EDGAR Online Pro Form 8-K for ONCOTHYREON INC. 12-Nov-2009Results of Operations and Financial Condition, Financial Statements and Exhibits Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provide...Click here to read the whole Article (external link)
Would you like to leave a comment about Oncothyreon Inc . ONTY
Find out what social network information about Oncothyreon Inc . are available on RealpenniesWorst 5 - Click here to find out what stocks have been voted down by our visitors and users
Besides Oncothyreon Inc . there is more great information available at Realpennies.com